Pierre Beaurang is Chief Business Officer of Nurix Therapeutics, Inc.. Currently has a direct ownership of 4,330 shares of NRIX, which is worth approximately $90,367. The most recent transaction as insider was on Aug 10, 2021, when has been sold 7,500 shares (Common Stock) at a price of $29.97 per share, resulting in proceeds of $224,775. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 4.33K
0% 3M change
0% 12M change
Total Value Held $90,367

Pierre Beaurang Transaction History

Date Transaction Value Shares Traded Shares Held Form
Aug 10 2021
SELL
Open market or private sale
$224,775 $29.97 p/Share
7,500 Reduced 63.4%
4,330 Common Stock
Aug 10 2021
BUY
Exercise of conversion of derivative security
$8,325 $1.11 p/Share
7,500 Added 38.8%
11,830 Common Stock
Jul 12 2021
SELL
Open market or private sale
$182,250 $24.3 p/Share
7,500 Reduced 63.4%
4,330 Common Stock
Jul 12 2021
BUY
Exercise of conversion of derivative security
$8,325 $1.11 p/Share
7,500 Added 38.8%
11,830 Common Stock
Jun 10 2021
SELL
Open market or private sale
$225,150 $30.02 p/Share
7,500 Reduced 63.4%
4,330 Common Stock
Jun 10 2021
BUY
Exercise of conversion of derivative security
$8,325 $1.11 p/Share
7,500 Added 38.8%
11,830 Common Stock
May 10 2021
SELL
Open market or private sale
$201,525 $26.87 p/Share
7,500 Reduced 63.4%
4,330 Common Stock
May 10 2021
BUY
Exercise of conversion of derivative security
$8,325 $1.11 p/Share
7,500 Added 38.8%
11,830 Common Stock
Apr 12 2021
SELL
Open market or private sale
$207,900 $27.72 p/Share
7,500 Reduced 63.4%
4,330 Common Stock
Apr 12 2021
BUY
Exercise of conversion of derivative security
$7,350 $0.98 p/Share
7,500 Added 38.8%
11,830 Common Stock
Mar 25 2021
BUY
Exercise of conversion of derivative security
$3,637 $0.84 p/Share
4,330 Added 50.0%
4,330 Common Stock
Mar 08 2021
SELL
Open market or private sale
$280,350 $37.38 p/Share
7,500 Reduced 100.0%
0 Common Stock
Mar 08 2021
BUY
Exercise of conversion of derivative security
$6,300 $0.84 p/Share
7,500 Added 50.0%
7,500 Common Stock
Feb 18 2021
SELL
Open market or private sale
$540,000 $36.0 p/Share
15,000 Reduced 100.0%
0 Common Stock
Feb 18 2021
BUY
Exercise of conversion of derivative security
$88,350 $5.89 p/Share
15,000 Added 50.0%
15,000 Common Stock
PB

Pierre Beaurang

Chief Business Officer
San Francisco, CA

Track Institutional and Insider Activities on NRIX

Follow Nurix Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells NRIX shares.

Notify only if

Insider Trading

Get notified when an Nurix Therapeutics, Inc. insider buys or sells NRIX shares.

Notify only if

News

Receive news related to Nurix Therapeutics, Inc.

Track Activities on NRIX